pharmaceutical costs<\/a> a major financial burden for American patients and taxpayers.<\/p>\n\n\n\nA similar initiative proposed five years ago during Trump\u2019s first term<\/em> was blocked by the courts. At the time, the administration projected the plan would save taxpayers more than US$85 billion over seven years. These savings were positioned against an annual national drug expenditure exceeding US$400 billion, according to government estimates.<\/p>\n\n\n\nAustralia\u2019s Bulk Buying Model Could Face Pressure<\/h2>\n\n\n\n
In Australia<\/em>, drugs are largely purchased in bulk under the Pharmaceutical Benefits Scheme (PBS) and offered to the public at significantly reduced prices. This model relies heavily on negotiated contracts and centralized purchasing, providing stability and cost control.<\/p>\n\n\n\nRob Nicholls<\/em>, senior researcher at the University of Sydney<\/em>, questioned the assumptions underlying Trump\u2019s analysis:<\/p>\n\n\n\n\nNot for the first time the Trump administration is comparing two completely different things – he told SkyNews.com.au<\/em>.<\/p>\n<\/blockquote>\n\n\n\nHe elaborated:<\/p>\n\n\n\n
\nWhat President Trump seems to think is, \u2018if prices go down in the States, the profitability of pharmaceutical businesses will stay the same. So therefore, prices might rise elsewhere\u2019.<\/p>\n<\/blockquote>\n\n\n\n
\nThat makes two big assumptions: First, all medicines are produced in the US, and shock horror, they’re not, and that all medicines have zero substitutability, which is not quite true.<\/p>\n<\/blockquote>\n\n\n\n
Nicholls added:<\/p>\n\n\n\n
\nThe assumption that all medicines have no substitutes and all medicines are produced in the States \u2013 if those two were valid, then he’d be right.<\/p>\n<\/blockquote>\n\n\n\n
Negotiation Challenges and Future Price Shifts<\/h2>\n\n\n\n
Lower U.S. prices could complicate future PBS negotiations and potentially result in higher costs for specific medications when contracts are up for renewal. Nicholls noted:<\/p>\n\n\n\n
\nIt will just mean a lot more work and for some drugs, they may well go up in price.<\/p>\n<\/blockquote>\n\n\n\n
The PBS might be forced to reassess procurement strategies, particularly for medicines with limited international alternatives or those produced in the U.S.<\/p>\n\n\n\n
Labor MP Dr Mike Freelander<\/em>, a former paediatrician, expressed confidence in Australia\u2019s regulatory mechanisms:<\/p>\n\n\n\n\nI don’t think there will be price rises for our community.<\/p>\n<\/blockquote>\n\n\n\n
\nWe\u2019ve had a long-standing system with the PBS and PBAC… we assess the drugs on their merit.<\/p>\n<\/blockquote>\n\n\n\n
\nWe have a good system where it’s a one provider system, where companies that produce these medications have to negotiate just with the PBS, and we are effective in getting the lowest possible process through that mechanism.<\/p>\n<\/blockquote>\n\n\n\n
Potential Blowback on u.s. Manufacturing Goals<\/h2>\n\n\n\n
Trump\u2019s plan could also undermine his industrial policy goals. While the \u201cmost favoured nation\u201d pricing is meant to protect U.S. consumers, the resulting price compression might discourage pharmaceutical production in the country. Nicholls warned:<\/p>\n\n\n\n
\nThat’s the real problem with all of the tariffs \u2013 that you could end up with an issue that actually comes back to bite in a way that the current US administration doesn’t seem to be able to foresee.<\/p>\n<\/blockquote>\n\n\n\n
Some manufacturers may choose to relocate operations abroad to maintain profitability, especially if U.S. prices drop but production costs remain high.<\/p>\n","protected":false},"excerpt":{"rendered":"
Donald Trump\u2019s push to match U.S. drug prices with the world\u2019s lowest has reignited global debate on pharmaceutical equity.
\nExperts caution the plan may shift financial pressure onto other countries and disrupt manufacturing goals.<\/p>\n","protected":false},"author":9,"featured_media":103554,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[44],"tags":[],"class_list":["post-103553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33","no-featured-image-padding"],"_links":{"self":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts\/103553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/comments?post=103553"}],"version-history":[{"count":4,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts\/103553\/revisions"}],"predecessor-version":[{"id":103558,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/posts\/103553\/revisions\/103558"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/media\/103554"}],"wp:attachment":[{"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/media?parent=103553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/categories?post=103553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/en.econostrum.info\/au\/wp-json\/wp\/v2\/tags?post=103553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}